The future of concussion biomarkers

Concussion biomarkers currently occupy a transitional space between experimental promise and limited clinical use. For decades, clinicians have relied on symptom checklists, neurological examinations, and neurocognitive tests to infer brain injury indirectly. These tools, while indispensable, are subjective, vulnerable to patient under-reporting or over-reporting, and often fail to capture subtle or delayed effects of mild traumatic brain injury. The push toward objective, quantifiable indicators of concussion has driven intensive research across molecular, imaging, and digital domains, creating a complex and rapidly evolving landscape.

At present, the most clinically advanced concussion biomarkers are specific brain-derived proteins that can be measured through blood tests. Two of the best known are glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1, often written as uchi-l1). These proteins are released into the bloodstream when brain cells, particularly astrocytes and neurons, are injured. A key milestone has been regulatory clearance for certain assays that measure GFAP and UCH-L1 to help determine the need for head CT scanning in adults with suspected mild traumatic brain injury. In this very narrow context, biomarkers are beginning to influence acute care decisions, although their use is far from universal and remains largely confined to emergency and trauma settings.

Beyond GFAP and UCH-L1, a broad panel of candidate proteins is being investigated. These include tau and phosphorylated tau, which are associated with axonal injury and neurodegeneration; neurofilament light chain, a structural axonal protein that may reflect diffuse axonal damage; and S100B, a calcium-binding protein released from astrocytes. Additional markers of inflammation, oxidative stress, and blood–brain barrier disruption are under active study. Most of these biomarkers remain in the realm of research rather than routine care, in part because their specificity for concussion versus other neurological insults is still being quantified, and their optimal sampling windows and cutoff values are not fully established.

In practical terms, current biomarker applications are largely short-term and event focused. Clinicians are most likely to consider biomarkers in the acute hours after injury, typically in emergency departments or high-level sports medicine environments. Here, the primary use case is triage: identifying patients at higher risk of intracranial lesions who might warrant advanced imaging, or reassuring clinicians when the probability of significant structural injury is low. This approach aims to reduce unnecessary CT scans, radiation exposure, and cost, while still maintaining safety. However, it does not yet provide fine-grained insight into long-term outcomes, cognitive trajectories, or risk of repeated injury.

Another major domain is sports-related concussion, where biomarkers hold strong theoretical appeal but limited present-day impact. Elite and professional sports organizations have invested heavily in biomarker research, exploring whether baseline and post-injury levels of GFAP, tau, neurofilament light, and other proteins could assist in return-to-play decisions. So far, the variability of biomarker responses between individuals, the influence of physical exertion, and logistical constraints on rapid testing have prevented widespread adoption. Sideline evaluation still relies predominantly on symptom reporting, observational assessment, and brief neurocognitive tools, with biomarkers mostly confined to controlled studies rather than everyday practice.

Military and veteran populations represent another critical focus area in the current landscape. Service members are often exposed to blast forces, repeated sub-concussive impacts, and complex polytrauma, all of which can complicate the clinical picture. In these settings, there is intense interest in biomarkers that can distinguish concussion from psychological stress, post-traumatic stress disorder, or chronic pain syndromes, and that might predict vulnerability to persistent symptoms. Although several multicenter trials are under way, biomarkers in military medicine are still primarily tools of diagnosis and research rather than standard screening devices.

Neuroimaging-based biomarkers, such as findings from diffusion tensor imaging or functional MRI, currently occupy an important position but remain mostly research tools. Conventional CT and MRI are often normal in concussion, which highlights the need for more sensitive methods that detect microstructural or functional changes. Advanced imaging can reveal subtle white matter alterations, connectivity disruptions, or metabolic shifts, but these techniques are expensive, require specialized expertise, and lack universally accepted thresholds or protocols. Consequently, they rarely guide acute clinical decision-making in mild traumatic brain injury outside of specialized centers.

Digital and physiological biomarkers are emerging but are still immature compared with blood-based measures. Wearable accelerometers and helmet-based sensors can record impact forces and rotational acceleration, yet correlations between impact metrics and clinical concussion are inconsistent. Eye-tracking technologies, balance platforms, and smartphone-based cognitive or oculomotor tests can capture subtle functional impairments, but standardization and normative data are still being developed. For now, these tools are often used to complement, rather than replace, traditional assessments, and they have not yet achieved the status of independently validated biomarkers.

Regulatory and professional guidelines currently incorporate concussion biomarkers only in limited ways. Some clinical algorithms acknowledge the role of specific blood tests in assessing the need for imaging after head trauma, but most guidelines still prioritize clinical judgment, symptom evolution, and standard neurological examination. Insurers and healthcare systems are cautious in reimbursing novel biomarker tests without robust evidence of cost-effectiveness and outcome improvement. As a result, access to cutting-edge biomarker assays is often confined to large academic centers, specialized concussion clinics, or clinical trials.

Despite these constraints, the conceptual framework surrounding concussion biomarkers is steadily maturing. There is growing recognition that no single biomarker is likely to capture the full complexity of brain injury across all patients, ages, mechanisms, and time points. Instead, the field is moving toward multi-modal approaches that integrate blood-based proteins, imaging signatures, and digital functional measures into composite indices or risk scores. At this stage, however, such multi-modal models are primarily being developed and tested in research cohorts rather than deployed at scale in routine care.

Equity and access issues also shape the current landscape. Most large studies have been conducted in high-resource settings, often with relatively homogenous populations, limiting the generalizability of identified biomarker thresholds. Children, older adults, women, and individuals from diverse racial and ethnic backgrounds remain underrepresented in many datasets. This imbalance raises concerns that early biomarker benchmarks may not perform equally well across populations, potentially exacerbating existing disparities in concussion care if not addressed systematically.

In everyday clinical practice, therefore, concussion biomarkers today play a supplementary role rather than a central one. Clinicians may use them for specific indications—such as evaluating the risk of intracranial injury in certain emergency department patients—while relying heavily on traditional clinical assessment for diagnosis, management, and return-to-activity decisions. The gap between what is technically measurable in controlled environments and what is feasible, affordable, and interpretable at the bedside remains a defining feature of the current state of the field.

Emerging blood-based and fluid biomarkers

The most active frontier in concussion biomarker development centers on blood-based and other fluid-derived measures that offer a minimally invasive window into brain pathology. Whereas early work focused on a small set of structural proteins released after injury, newer studies are expanding both the types of molecules examined and the clinical questions they aim to answer. These efforts span acute triage, prognosis, monitoring of recovery, and identification of individuals at risk for prolonged or recurrent problems, with blood tests increasingly serving as the backbone of large-scale diagnosis and research programs.

Within this emerging ecosystem, GFAP and UCH-L1 remain anchor molecules, but their role is shifting from simple yes/no indicators of intracranial injury to components of more nuanced risk stratification models. Researchers are characterizing how the concentration, rise and fall over time, and relative balance of these proteins correlate with symptom severity, neuroimaging abnormalities, and cognitive trajectories. Serial sampling, extending beyond the first few hours after injury, suggests that the time course of GFAP and UCH-L1 may distinguish transient disruptions from more persistent injury processes, especially when paired with clinical and imaging data.

Neurofilament light chain (NfL) has emerged as one of the most promising markers of axonal damage in concussion and repetitive head impact exposure. Initially studied in more severe traumatic brain injury and neurodegenerative diseases, NfL can now be measured in blood at very low concentrations using ultrasensitive assays. In athletes, elevations in NfL have been observed following concussive and even sub-concussive events, sometimes persisting for weeks after symptom resolution. In military cohorts, higher NfL levels have been associated with blast exposure and may correlate with white matter alterations on diffusion imaging. These observations raise the possibility that NfL could help quantify cumulative axonal stress across a season, career, or deployment.

Tau and phosphorylated tau (p-tau) occupy a particularly important place at the intersection of acute injury and long-term neurodegeneration. After concussion, total tau may rise transiently, reflecting diffuse axonal injury, while specific phosphorylated species could hint at pathological processes linked to chronic traumatic encephalopathy and related disorders. Plasma p-tau isoforms that have transformed Alzheimer’s disease diagnostics are now being evaluated in repetitive head trauma, with early data suggesting associations between higher levels, symptom burden, and structural or functional imaging changes. The critical question is whether tau-based blood tests can distinguish individuals likely to recover fully from those at risk for progressive protein aggregation and neurocognitive decline.

Beyond these structural and cytoskeletal proteins, inflammatory and immune mediators constitute a rapidly expanding category of concussion biomarkers. Cytokines such as interleukin-6, interleukin-1β, and tumor necrosis factor-α, as well as chemokines and complement components, show dynamic changes in the hours and days following injury. Patterns of early hyperinflammation followed by prolonged low-grade activation may correlate with symptom persistence, mood disturbances, and sleep disruption. Complementary markers of microglial activation, including soluble TREM2 and other immune-related molecules, are being explored as indicators of neuroinflammatory cascades that could link single or repeated concussions to later-life neurodegenerative vulnerability.

Markers of blood–brain barrier (BBB) integrity represent another emerging class. Proteins normally sequestered within the central nervous system, such as albumin in cerebrospinal fluid relative to serum, have long been used to infer barrier disruption in other conditions. In concussion, investigators are now testing whether specific endothelial and tight-junction proteins, as well as matrix metalloproteinases, can be measured in blood to capture subtle BBB leakage that may accompany otherwise “mild” injuries. If validated, such measures could complement neuronal and glial biomarkers by indicating the degree to which systemic immune factors gain access to the brain after trauma.

Metabolomic and lipidomic approaches expand the biomarker search beyond individual proteins to comprehensive molecular signatures. High-throughput platforms can profile hundreds to thousands of small molecules in blood, saliva, or cerebrospinal fluid, yielding metabolic fingerprints of concussion. Alterations in energy metabolism intermediates, amino acids, and membrane lipids have been documented following mild traumatic brain injury, some of which normalize with recovery while others persist. Machine learning models trained on these multidimensional datasets are beginning to classify injured versus non-injured individuals and predict symptom duration with promising accuracy, suggesting that panel-based signatures may ultimately outperform single-analyte tests.

Saliva and other easily obtainable biofluids are gaining attention for their potential to enable sideline or point-of-care assessment. Salivary microRNAs, short non-coding RNA molecules that regulate gene expression, show distinct patterns after concussion and may reflect neuronal stress, inflammation, and synaptic plasticity changes. Because saliva collection is non-invasive and does not require venipuncture or specialized staff, salivary biomarkers could be particularly useful in youth sports, schools, and remote settings. Pilot studies combining salivary microRNA profiles with symptom questionnaires and cognitive testing have achieved moderate to high classification accuracy for concussion, though large-scale validation is still needed.

Cerebrospinal fluid (CSF) remains the most direct window into central nervous system biochemistry, and advanced CSF assays continue to inform blood-based biomarker development. In select research cohorts and in patients undergoing lumbar puncture for clinical reasons, CSF levels of tau, p-tau, NfL, GFAP, synaptic proteins, and inflammatory markers are being mapped against blood levels. These paired measurements help define which molecules cross into circulation reliably and at what time points, guiding the selection of candidates for routine blood tests. CSF analyses are also critical for understanding the relationship between acute concussion biomarkers and long-term neuropathology observed in postmortem studies of chronic traumatic encephalopathy and related conditions.

Technological advances in assay sensitivity and format underpin many of these developments. Single-molecule and digital immunoassays can detect femtomolar concentrations of brain-derived proteins, transforming previously “undetectable” signals into quantifiable metrics. Multiplex platforms allow simultaneous measurement of dozens of analytes from a small sample volume, facilitating the creation of composite indices that integrate structural, inflammatory, vascular, and metabolic information. Efforts are also under way to miniaturize these technologies into cartridge-based or handheld devices suitable for emergency departments, athletic facilities, and even in-home monitoring, although maintaining analytical rigor outside centralized laboratories remains a major challenge.

One emerging paradigm is the use of multivariate biomarker panels tailored to specific clinical questions rather than a universal concussion test. For acute triage, panels emphasizing GFAP, UCH-L1, and other markers tightly linked to intracranial lesions may be most useful. For predicting prolonged symptoms, combinations of neuronal, glial, and inflammatory markers may provide better prognostic information. For monitoring repetitive exposure, longitudinal tracking of NfL, tau, and selected inflammatory mediators might be prioritized. By moving toward indication-specific panels, researchers hope to capture the multidimensional nature of brain injury while acknowledging that different mechanisms predominate at different stages and in different populations.

Crucially, emerging biomarker work is beginning to address populations that have historically been underrepresented in concussion studies. Pediatric cohorts are being followed with age-adjusted protein and metabolite panels to account for developmental differences in baseline levels and response to injury. Studies focused on women and gender-diverse individuals are examining how hormonal status, menstrual cycle phase, and contraception or hormone therapy influence biomarker profiles. Investigations in older adults are exploring how preexisting cerebrovascular disease, neurodegeneration, and polypharmacy affect biomarker interpretation. These initiatives aim to ensure that evolving blood and fluid biomarkers are valid, safe, and equitable across the full spectrum of people who sustain concussions.

Across these domains, the boundary between diagnosis and research is increasingly porous. Many of the most sophisticated biomarker signatures currently exist only in specialized laboratories and multicenter consortia, yet their design is explicitly oriented toward eventual clinical translation. As large, diverse datasets accumulate and analytical methods mature, the expectation is that select panels will move from discovery studies into standardized, regulated assays. The trajectory of emerging blood-based and fluid biomarkers thus reflects a steady shift from single-molecule detection toward integrated, systems-level characterization of concussion biology, laying the groundwork for more precise risk stratification, monitoring, and intervention in the years ahead.

Advances in neuroimaging and digital biomarkers

Advanced neuroimaging has become a critical counterpart to blood tests and fluid biomarkers, offering a structural and functional lens on concussion that can reveal changes invisible to standard CT or MRI. Among the most studied methods is diffusion tensor imaging, which measures the directional movement of water along white matter tracts. In concussion, subtle reductions in fractional anisotropy and increases in mean diffusivity have been reported in key pathways such as the corpus callosum, internal capsule, and frontal-subcortical circuits. These microstructural alterations are often modest at the individual level but show consistent group-level patterns, especially when combined with clinical severity scores, neurocognitive performance, and levels of proteins such as NfL or GFAP.

Beyond traditional diffusion tensor metrics, newer diffusion models such as neurite orientation dispersion and density imaging, diffusion kurtosis imaging, and constrained spherical deconvolution are refining our understanding of concussion-related white matter injury. These techniques attempt to separate intra-axonal, extra-axonal, and free-water compartments, capturing more nuanced aspects of axonal swelling, demyelination, and glial responses. When paired with longitudinal designs, they can track partial recovery of white matter integrity or the emergence of more chronic abnormalities following repeated injuries. The challenge is to translate these complex metrics into robust, clinically interpretable biomarkers that can augment both diagnosis and research without requiring highly specialized expertise at every site.

Functional MRI has expanded the biomarker landscape by probing how concussion alters brain network activity and connectivity rather than just structure. Resting-state fMRI, which measures spontaneous low-frequency fluctuations in blood oxygen level–dependent signals, has revealed disruptions in networks that underlie attention, executive function, and default-mode processing. For example, reduced connectivity within the default mode network and increased connectivity in salience or frontoparietal networks have been interpreted as a compensatory rebalancing of neural resources after injury. Task-based fMRI adds another dimension by examining how the brain recruits specific regions during working memory, inhibitory control, or visual processing tasks, often revealing hyperactivation or inefficient recruitment in concussed individuals even when behavioral performance appears normal.

Quantitative structural MRI techniques, including volumetric analysis, cortical thickness mapping, and voxel-based morphometry, have been applied to individuals with both single and repetitive concussions. While clear atrophy is uncommon in the acute phase of mild traumatic brain injury, subtle regional volume differences have been reported in chronic or repeatedly injured populations, particularly in the hippocampus, corpus callosum, and frontal lobes. Automated, atlas-based segmentation pipelines and machine learning classifiers are being trained on large datasets to detect these subtle changes and to generate individualized risk scores. In combination with circulating biomarkers such as tau, p-tau, or UCH-L1, these imaging signatures may eventually help stratify patients according to their risk for persistent symptoms or later neurodegenerative disease.

Another promising avenue lies in quantitative susceptibility mapping, magnetic resonance spectroscopy, and perfusion imaging. Quantitative susceptibility mapping can detect microhemorrhages and iron deposition associated with diffuse axonal injury, while magnetic resonance spectroscopy provides a window into neurochemical disturbances, such as changes in N-acetylaspartate, glutamate, and choline. Arterial spin labeling and dynamic susceptibility contrast imaging assess cerebral blood flow and perfusion, revealing potential dysautonomia or microvascular dysfunction after concussion. These advanced modalities remain resource-intensive, but as acquisition protocols and analysis pipelines standardize, they are being increasingly incorporated into multicenter concussion studies, where they serve as intermediate endpoints and mechanistic readouts alongside blood tests and symptom measures.

Positron emission tomography has also entered the field, particularly for investigating the long-term sequelae of repetitive head trauma. Tau-targeted tracers, amyloid ligands, and markers of microglial activation are being used to explore whether patterns of tracer uptake correlate with clinical symptoms, cognitive decline, or exposure histories in athletes, veterans, and others at risk. While PET is unlikely to play a broad role in acute concussion management due to cost and radiation exposure, it provides crucial mechanistic insight into the relationship between early injury events and later-life neuropathology. Integration of PET findings with plasma p-tau, GFAP, and NfL levels is beginning to bridge molecular and imaging biomarkers across the continuum from mild injury to potential neurodegeneration.

Parallel to these neuroimaging advances, digital biomarkers are emerging from the proliferation of wearable sensors, smartphone technologies, and connected devices. In sports, helmet- and mouthguard-mounted accelerometers and gyroscopes record linear and rotational accelerations during impacts, generating detailed exposure profiles across seasons and careers. Although the correlation between raw impact magnitude and clinical concussion remains imperfect, derived metrics such as cumulative impact burden, frequency of high-risk hits, and head kinematic “signatures” are being developed as surrogate markers of mechanical brain stress. When combined with incident symptoms, neurocognitive changes, and fluid biomarkers like GFAP or NfL, these exposure metrics may help clarify individual thresholds for injury and recovery.

Outside of structured sports, consumer wearables and medical-grade devices are turning everyday behavior into a rich source of potential concussion biomarkers. Continuous monitoring of sleep patterns, heart rate variability, physical activity, and circadian rhythms can reveal subtle shifts after injury. For example, reduced sleep efficiency, fragmentation of rest–activity cycles, or altered autonomic balance may persist long after acute symptoms resolve. Algorithms trained on longitudinal wearable data can flag deviations from individual baselines that may indicate ongoing physiological stress or incomplete recovery, offering an objective complement to self-reported symptoms that are susceptible to under-reporting or bias.

Digital oculomotor and vestibular measurements form another central pillar of emerging concussion biomarkers. Eye-tracking systems, ranging from high-precision infrared cameras to smartphone-based tools, assess saccades, smooth pursuit, vergence, and pupillary responses during standardized tasks. Concussion-related impairments often manifest as increased latency, decreased velocity, or reduced accuracy of eye movements, as well as instability in gaze fixation. Similarly, computerized balance platforms and inertial measurement units embedded in headsets, belts, or shoes quantify postural sway, gait variability, and response to perturbations. These measurements can detect subtle motor and vestibular deficits that escape routine exams, providing continuous or repeatable objective data over the course of recovery.

Neurocognitive and behavioral digital biomarkers are being built from computerized testing batteries, mobile apps, and passive smartphone signals. Traditional paper-based tests of memory, attention, and processing speed are now being adapted into brief, repeatable digital tasks that can be administered on tablets or phones in clinics, on sidelines, or at home. More experimentally, passive data such as typing dynamics, speech prosody, social media usage patterns, and geolocation variability are being examined for changes following concussion. Shifts in typing speed, error rates, speech tempo, or daily movement patterns may indicate cognitive fatigue, mood changes, or reduced engagement with usual activities, even in individuals who self-report feeling “back to normal.”

Advances in analytics are essential for converting raw digital signals into clinically meaningful biomarkers. Machine learning and deep learning models can assimilate high-dimensional data streams from eye tracking, balance sensors, wearables, and smartphone interactions, extracting patterns that correlate with symptom burden, imaging abnormalities, or biochemical markers. For example, composite indices derived from oculomotor metrics, reaction times, and postural stability may classify concussion status with greater accuracy than any single measure alone. Importantly, these models can incorporate individual baselines where available, emphasizing within-person changes rather than relying exclusively on population norms that may not account for age, sex, sport, or cultural differences.

Integration of neuroimaging and digital biomarkers with blood-based measures is reshaping concussion research design. Multimodal studies now routinely collect advanced MRI, head impact exposure data, wearable-derived physiological metrics, and serial blood samples for proteins such as GFAP, UCH-L1, tau, and NfL. These rich datasets allow investigators to test hypotheses about the causal chain from mechanical forces to microstructural and functional brain changes, systemic responses, symptom trajectories, and long-term outcomes. In this framework, neuroimaging may serve as a mechanistic bridge between exposure metrics and molecular markers, while digital measures provide granular, ecologically valid assessments of everyday functioning.

One emerging use case for neuroimaging and digital biomarkers is in determining safe return-to-activity, whether in sports, military operations, or civilian work. Traditional clearance decisions hinge heavily on symptom resolution and brief neurocognitive testing, yet mounting evidence suggests that some individuals exhibit ongoing network dysfunction or physiological dysregulation despite feeling well. Abnormal resting-state connectivity patterns, persistent diffusion changes, or ongoing oculomotor and balance abnormalities can all signal incomplete recovery. Pilot protocols are exploring tiered return-to-play algorithms in which digital and imaging biomarkers must normalize or return to a personalized range, in addition to symptom resolution, before full clearance is granted.

Telemedicine and remote monitoring are accelerating the adoption of digital biomarkers, particularly for patients in rural or underserved areas who may not have access to advanced imaging or specialty concussion clinics. Smartphone-based eye tracking, balance assessments using built-in accelerometers, and cloud-connected cognitive tests can be deployed at home, with results transmitted to clinicians for interpretation. This distributed model allows for more frequent, low-burden assessments and may capture early signs of deterioration or non-recovery that would otherwise be missed between in-person visits. As regulatory frameworks adapt, these tools are likely to play an increasing role in both acute follow-up and long-term surveillance after concussion.

Despite their promise, advanced neuroimaging and digital biomarkers face several barriers before they can be fully integrated into routine clinical pathways. Imaging protocols vary widely across scanners, institutions, and countries, complicating the development of universal thresholds and reference values. Digital tools, meanwhile, must contend with differences in hardware, operating systems, user behavior, and data privacy regulations. There is also a risk of overfitting models to select cohorts such as collegiate athletes or military personnel, limiting generalizability to youth sports, older adults, or community populations. Addressing these issues requires harmonized acquisition standards, open data sharing initiatives, and rigorous external validation in diverse groups.

Importantly, as neuroimaging and digital biomarkers mature, they are beginning to highlight the heterogeneity of concussion rather than reinforcing a single, uniform injury model. Some individuals show robust imaging abnormalities with relatively mild symptoms, while others report disabling complaints despite minimal structural or functional changes on advanced scans. Similarly, certain patients exhibit pronounced digital oculomotor or balance deficits, whereas others primarily demonstrate cognitive, affective, or sleep disturbances captured through different digital modalities. Recognizing and characterizing these distinct biomarker “phenotypes” is a crucial step toward tailoring management strategies and developing targeted interventions that reflect the multifaceted biology of concussion.

Challenges in validation and clinical implementation

Translating promising concussion biomarkers into tools that reliably guide real-world care is constrained first by the fundamental complexity and variability of mild traumatic brain injury itself. No two concussions are exactly alike; mechanisms of injury, preexisting health, genetic background, and prior exposure history all influence how the brain responds. This biological heterogeneity produces wide inter-individual variation in biomarker levels, imaging findings, and digital metrics, even among patients with similar symptom profiles. As a result, defining universal “normal” and “abnormal” thresholds for markers such as GFAP, UCH-L1, tau, or neurofilament light is challenging, particularly when these proteins are also altered in other neurological or systemic conditions.

Timing of measurement creates another major obstacle. Many candidate biomarkers show rapid, non-linear trajectories after injury, rising and falling over hours to days. Studies differ widely in when blood tests, imaging, or digital assessments are performed, making it difficult to compare results or synthesize evidence across cohorts. A marker that is highly discriminative at six hours post-injury may be far less informative at 24 or 72 hours, yet clinical presentations occur throughout this window and beyond. Without standardized sampling schedules and clear evidence about the optimal time points for each analyte or modality, clinicians risk misinterpreting values obtained outside the carefully controlled conditions of research protocols.

Analytical and pre-analytical variability further complicate validation. Differences in sample collection tubes, handling, processing times, storage conditions, and assay platforms can significantly influence measured concentrations of brain-derived proteins. Even widely studied markers like GFAP and UCH-L1 yield different absolute values depending on the specific commercial kit or laboratory method used. In imaging, scanner manufacturer, field strength, sequence parameters, and post-processing pipelines all introduce variability. For digital biomarkers, hardware differences between smartphones, sensors, and eye-tracking systems can alter signal quality. Harmonizing these technical factors across institutions and countries is resource-intensive but essential for establishing robust reference ranges and cutoffs.

Most published studies to date have been conducted in relatively small, highly selected populations, which limits external validity. Many early-phase investigations enroll collegiate athletes, active-duty military personnel, or patients presenting to tertiary-care emergency departments, all of whom differ in important ways from community-dwelling youth, older adults, and people with comorbid conditions. Underrepresentation of women, children, older individuals, and racial and ethnic minorities is common. This sampling bias raises concerns that thresholds derived from narrow cohorts will not generalize, potentially leading to under-diagnosis or over-diagnosis in groups whose baseline biomarker distributions or responses to injury differ from those of the discovery population.

Another challenge is distinguishing the specific contribution of concussion from that of co-occurring injuries and stressors. Many patients with head trauma also sustain orthopedic injuries, pain, sleep disruption, psychological stress, or intoxication, all of which can influence inflammatory markers, autonomic measures, and behavioral digital signatures. In such multifactorial contexts, attributing an elevated cytokine level, altered heart rate variability, or slowed cognitive performance solely to mild brain injury is difficult. Without careful control groups and longitudinal designs that parse these overlapping influences, there is a risk of overstating the brain specificity of certain biomarkers and misguiding clinical decisions.

Regulatory pathways and evidentiary standards create their own set of hurdles. For biomarkers to receive regulatory clearance as in vitro diagnostic devices or to be incorporated into clinical guidelines, they must demonstrate analytical validity, clinical validity, and clinical utility. Analytical validity demands rigorous proof that assays reliably and reproducibly measure the intended analyte across laboratories and over time. Clinical validity requires strong, independent evidence that biomarker levels correlate with clinically meaningful outcomes such as intracranial lesions, prolonged symptoms, or functional impairment. Clinical utility goes further, asking whether using the biomarker actually improves patient outcomes, safety, or cost-effectiveness compared with standard care. Many concussion markers, particularly in imaging and digital domains, are still in the clinical validity phase, with few large randomized or pragmatic trials showing that their use changes management or outcomes.

Health system constraints and workflow considerations often limit implementation even when analytical and clinical validity are established. Emergency departments operate under pressure to make rapid decisions, with limited tolerance for tests that add turnaround time or complexity. If blood tests require specialized processing or are available only through centralized laboratories, clinicians may be reluctant to incorporate them into acute triage algorithms. Advanced MRI or PET imaging is costly, time-consuming, and not universally available, particularly in rural or low-resource settings. Digital biomarkers that require proprietary hardware, lengthy calibration, or intensive data interpretation may not fit easily into busy clinics or sideline environments where staff have limited training and time.

Interpretability and communication present further challenges. Clinicians already face an overload of diagnostic information from history, physical examination, neurocognitive testing, and conventional imaging. Adding novel biomarkers with unfamiliar units, dynamic ranges, and context-dependent meanings can create confusion rather than clarity. For example, mildly elevated GFAP in an otherwise stable patient with a normal CT scan might be interpreted as either residual injury, an incidental finding, or laboratory noise. Without clear, evidence-based guidance on how to act on specific biomarker values—such as when to image, admit, observe, or clear a patient for return to activity—there is a risk of inconsistent use, over-reliance, or disregard.

Economic and reimbursement issues also shape whether biomarkers move from diagnosis and research environments into routine clinical use. New assays, imaging sequences, and digital platforms carry development, acquisition, and maintenance costs that must be weighed against potential benefits. Payers often require strong evidence that a test reduces downstream expenditures, such as by preventing unnecessary CT scans, hospital admissions, or repeat clinic visits, before agreeing to reimburse it. In many regions, reimbursement pathways for digital health tools are immature or absent, making it difficult for institutions to justify investing in devices and analytic platforms. These economic barriers can slow adoption and exacerbate disparities between well-resourced academic centers and community practices.

Ethical, legal, and social considerations add another layer of complexity, particularly in sports and military contexts where concussion biomarkers may influence eligibility, deployment, or contract decisions. Athletes and service members may worry that abnormal blood or imaging results could be used against them, creating incentives to avoid testing or under-report symptoms. Questions arise about who owns and controls biomarker data, how long it is stored, and under what circumstances it can be shared with teams, employers, or insurers. Clear policies and safeguards are required to prevent misuse and to ensure that biomarker information is used to protect, rather than penalize, individuals at risk.

For digital biomarkers, data privacy and security concerns are especially prominent. Continuous monitoring of movement, sleep, speech, or smartphone usage generates highly personal datasets that can reveal health status, behavior patterns, and even aspects of mental health. Ensuring encryption, secure storage, and appropriate consent is technically and administratively demanding. Regulatory frameworks such as HIPAA in the United States and GDPR in Europe impose strict requirements on how such data can be collected, processed, and shared, which may slow innovation or limit cross-border research collaborations if not addressed proactively.

Standardization and harmonization of digital and imaging biomarkers lag far behind those of traditional laboratory tests. While reference ranges for many blood-based proteins can be established in large population cohorts, it is much more difficult to define universal thresholds for metrics like resting-state connectivity strength, postural sway, or eye-tracking latency, which are influenced by age, device type, environmental conditions, and task instructions. Variations in software versions, firmware updates, and analysis algorithms can change outputs subtly but meaningfully over time. Without common data elements, shared protocols, and transparent reporting standards, combining datasets across sites and validating models externally becomes problematic.

Machine learning and artificial intelligence offer powerful tools for integrating multimodal data, but they introduce their own validation and implementation challenges. Models trained on high-dimensional datasets from select populations risk overfitting to idiosyncratic patterns that do not generalize. Many algorithms are “black boxes,” making it difficult for clinicians to understand why a certain risk score or classification was generated. Regulatory agencies are still developing frameworks for evaluating adaptive and continuously learning systems, particularly when they affect high-stakes decisions such as return-to-play or fitness for duty. Ensuring fairness, transparency, and robustness across diverse populations is an ongoing technical and ethical challenge.

Longitudinal validation is particularly demanding yet essential. Many hoped-for applications of concussion biomarkers involve predicting long-term outcomes, such as persistent symptoms, cumulative effects of repetitive head impacts, or risk of later-life neurodegenerative disease. Demonstrating that early biomarker levels or patterns truly forecast such outcomes requires years of follow-up, large cohorts, and careful control for confounding variables like education, cardiovascular risk, and mental health. Attrition, changes in technology over time, and evolving clinical practices all complicate these long-term studies. Until robust longitudinal evidence accumulates, the use of biomarkers for prognostication must remain cautious.

Another underappreciated barrier is the need to align biomarker endpoints with outcomes that matter to patients, families, and clinicians. While many studies focus on predicting neuroimaging abnormalities or neuropsychological test scores, patients often prioritize returning to school, work, sport, and social activities without symptoms. Bridging this gap requires incorporating patient-reported outcomes, quality-of-life measures, and functional assessments into validation studies. Biomarkers that correlate strongly with subtle imaging changes but weakly with day-to-day function may be less compelling for clinical adoption than those that capture real-world recovery and participation.

Implementing biomarkers in pediatric populations introduces distinct scientific and practical issues. Developmental changes in brain structure, metabolism, and immune function mean that baseline levels and response patterns of many proteins and digital metrics differ markedly by age. Normative datasets must therefore be stratified by narrow age bands, and cutoff values may need to be dynamic rather than static. Obtaining blood samples, advanced imaging, or lengthy digital assessments from young children can be difficult, and ethical thresholds for research participation are higher. These factors slow the accumulation of robust pediatric data and complicate efforts to create age-appropriate clinical tools.

Integration of biomarkers into clinical pathways requires sustained education and culture change among clinicians, athletic trainers, and other frontline providers. Many practitioners are understandably skeptical of adopting new tests without clear evidence and practical guidelines, particularly in an area as nuanced and symptom-driven as concussion. Training programs must explain not only how to order and interpret biomarkers, but also their limitations, sources of error, and appropriate role alongside traditional assessment. Without such efforts, there is a risk that biomarkers will be used inconsistently, misapplied as definitive arbiters of injury or recovery, or ignored altogether despite their potential value.

Future directions and personalized concussion care

The next phase of concussion biomarker development is poised to move from broad discovery toward precision applications that reflect the unique biology, context, and goals of each individual. Rather than searching for a single universal marker or cutoff, future approaches are likely to rely on integrated “profiles” that combine molecular signatures, imaging findings, and digital metrics with clinical history. These profiles will be used not just for diagnosis and research, but also to guide preventive strategies, personalize treatment plans, and monitor recovery trajectories in real time.

Central to this evolution is the shift toward individualized baseline characterization. In high-risk groups such as athletes, military personnel, and certain occupational cohorts, it is increasingly feasible to collect pre-injury data on cognitive performance, balance, eye movements, sleep, mood, and even low-level concentrations of brain-derived proteins such as GFAP, UCH-L1, and neurofilament light. These baselines create a personalized reference frame against which post-injury changes can be interpreted more accurately than with population norms alone. Over time, baseline programs may extend to broader communities through routine health visits or digital health platforms, particularly if sample collection and digital testing become inexpensive and scalable.

Personalized concussion care will also draw on multivariate risk models that integrate traditional clinical variables with biomarker data. These models might incorporate age, sex, concussion history, genetic variants, comorbidities such as migraine or mood disorders, as well as blood tests, imaging metrics, and digital indicators of sleep or autonomic function. Using machine learning and other analytic methods, this information can be distilled into individualized risk scores for outcomes such as prolonged recovery, recurrent injury, or persistent vestibular or cognitive symptoms. Clinicians could then stratify patients into different care pathways—ranging from brief observation to intensive multidisciplinary follow-up—based on objective projections rather than relying solely on early symptom reports.

Therapeutic decision-making is another area where personalized biomarker strategies are likely to play an expanding role. As pharmacologic and non-pharmacologic interventions for concussion advance, biomarkers may help identify which patients are most likely to benefit from particular therapies and when those treatments should be deployed. For example, individuals with prominent inflammatory signatures or sustained elevations in certain cytokines could be prioritized for anti-inflammatory or immunomodulatory approaches, while those with marked autonomic or sleep disruption on wearable-derived metrics might be directed toward targeted rehabilitation or neuromodulation. Similarly, persistent abnormalities in structural or functional imaging could justify more intensive cognitive rehabilitation or constraints on rapid return to high-risk activities.

In sports and military settings, personalized thresholds for exposure and recovery are likely to become increasingly important. Instead of applying a uniform rule across an entire team or unit, algorithms could synthesize impact kinematics, serial blood biomarkers, and digital performance metrics to determine each individual’s tolerance for repeated head impacts or physical stress. An athlete whose biomarkers and neurocognitive measures normalize quickly after a concussion might follow a standard graduated return-to-play protocol, whereas another with lingering microstructural imaging changes or elevated NfL levels might require extended rest, modified training loads, or alternative roles. In high-stakes environments, these personalized thresholds could be integrated into real-time decision dashboards for medical staff and commanders.

Longitudinal monitoring will be a defining feature of future concussion care models, especially for individuals with recurrent injuries or chronic symptoms. Rather than relying on sporadic clinic visits, continuous or periodic remote assessments using smartphones, wearables, and home-based cognitive or oculomotor tools will track the evolution of recovery over weeks and months. Blood tests could be obtained at strategic intervals through point-of-care devices or decentralized sampling programs, enabling clinicians to correlate subjective symptoms with objective trends in proteins associated with axonal injury, glial activation, or blood–brain barrier disruption. This ongoing surveillance may reveal subtle inflection points—such as plateauing or worsening biomarker trajectories—that prompt earlier intervention or change in treatment strategy.

Future directions also include developing biomarker-informed subtyping of concussion. Current clinical labels such as “cognitive,” “vestibular,” “migraine,” or “anxiety/mood” subtypes are based largely on symptom patterns and examination findings. By layering in molecular, imaging, and digital data, more biologically grounded phenotypes may emerge. One subtype, for example, might be characterized by predominant white matter microstructural abnormalities and elevated axonal proteins, another by persistent neuroinflammatory signatures and sleep disruption, and yet another by dysregulated autonomic and vascular responses without overt structural changes. These phenotypes could guide both targeted clinical management and the design of more focused interventional trials.

As personalized approaches mature, equity and inclusivity must be built into every stage of development. Biomarker thresholds and predictive models that work well in one demographic or cultural context may perform poorly in others if they are not derived from diverse datasets. Future research agendas will need to prioritize enrollment of children, older adults, women, and underrepresented racial and ethnic groups, as well as individuals with preexisting neurological or psychiatric conditions. Culturally sensitive methods of digital assessment, language-appropriate interfaces, and community-engaged research practices will be essential to ensure that personalized concussion care does not widen existing disparities in access to advanced diagnostics and treatments.

Implementation science will play a crucial role in translating personalized biomarker strategies from specialized centers to everyday practice. This includes designing workflows that embed biomarker collection and interpretation into existing clinical pathways without overburdening staff or delaying care. Decision-support tools integrated into electronic health records can automatically interpret test results in context, flag high-risk patients, and suggest evidence-based next steps. For example, if a patient presents with mild symptoms but has elevated GFAP and specific imaging abnormalities, the system might recommend observation or additional imaging rather than immediate discharge. Conversely, normal biomarker patterns in a low-risk context could support safe discharge with remote follow-up, reducing unnecessary admissions.

Another future direction involves strengthening the feedback loop between clinical care and research. With appropriate consent and robust privacy safeguards, de-identified biomarker and outcome data from routine practice can be fed back into research databases, continuously refining predictive models and reference ranges. In this learning health system model, every concussion encounter contributes to better understanding of injury mechanisms, recovery patterns, and treatment responses. Conversely, insights from large-scale research consortia can be rapidly translated into updated clinical guidelines, digital tools, and decision-support algorithms that disseminate best practices widely.

Technological innovation will continue to lower barriers to personalized biomarker use. Miniaturized analyzers capable of measuring panels of brain-derived proteins at the point of care, combined with affordable cloud-based analytics, can bring sophisticated testing to community clinics, schools, and field environments. Advances in sensor technology may enable more comfortable, unobtrusive wearables that capture a wider range of physiological signals with higher fidelity, while adaptive testing algorithms will tailor digital cognitive and oculomotor assessments to each individual’s baseline and performance history. As these tools converge, personalized concussion care pathways could be initiated in emergency departments, on sidelines, in primary care offices, or even in patients’ homes, with specialist input available via telemedicine as needed.

Ethical frameworks for personalized concussion care will need to evolve in parallel. Biomarker-informed risk estimates can have profound implications for life choices, including whether an athlete continues in a contact sport or a service member remains in a combat role. Future practice will require transparent communication about what biomarkers can and cannot predict, shared decision-making that respects patient values and goals, and safeguards against coercion or discrimination. Policies will need to address the handling of incidental findings, the long-term storage and secondary use of biospecimens and digital data, and the rights of individuals to access or delete their information.

Education across stakeholder groups will be a critical enabling factor. Patients, families, coaches, trainers, and employers will require clear, accessible explanations of how biomarker information is used to guide personalized care, including the limitations and uncertainties inherent in predictive models. Clinicians will need training not only in ordering and interpreting tests, but also in integrating disparate modalities—such as imaging, blood tests, and digital metrics—into coherent, individualized management plans. Researchers and developers, for their part, must engage with frontline users to understand practical needs and constraints, ensuring that emerging technologies are usable, acceptable, and responsive to the realities of diverse care settings.

Ultimately, future directions in concussion biomarkers are moving toward a model in which objective measures are seamlessly embedded in a broader ecosystem of personalized care. Rather than functioning as isolated tests, biomarkers will act as dynamic inputs to continuously updated risk assessments and care plans, helping clinicians answer nuanced questions: Who is at greatest risk of prolonged recovery? Who can return safely to play, duty, or work? Who requires targeted rehabilitation, and of what type and intensity? By aligning biomarker development with these concrete clinical decisions and by tailoring interpretations to the individual rather than the average patient, the field aims to transform concussion management from a largely reactive, symptom-driven practice into a proactive, precision-oriented discipline.